Loading...
While the last decade has seen dramatically declining incidence of most healthcare-associated infections, rates of Clostridioides difficile disease have changed less markedly — moreover, as decreases in healthcare-acquired C. difficile infections (CDIs) have been counterbalanced by rising incidence in the community, new approaches to CDI prevention are urgently needed. Now, a multidisciplinary research team has developed several promising candidate multivalent mRNA lipid nanoparticle (mRNA-LNP) vaccines.
The researchers first defined highly conserved target sequences of the C. difficile toxin A (TcdA) and toxin B (TcdB) genes along with a C. difficile metalloproteinase virulence factor (PPEP-1). The candidate bivalent (TcdA/TcdB) and trivale…